GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Galapagos NV (NAS:GLPG) » Definitions » EV-to-Revenue
中文

Galapagos NV (Galapagos NV) EV-to-Revenue : -8.03 (As of Apr. 24, 2024)


View and export this data going back to 2015. Start your Free Trial

What is Galapagos NV EV-to-Revenue?

EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, Galapagos NV's enterprise value is $-2,038.5 Mil. Galapagos NV's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 was $254.0 Mil. Therefore, Galapagos NV's EV-to-Revenue for today is -8.03.

The historical rank and industry rank for Galapagos NV's EV-to-Revenue or its related term are showing as below:

GLPG' s EV-to-Revenue Range Over the Past 10 Years
Min: -8.31   Med: 12.23   Max: 48.38
Current: -7.98

During the past 13 years, the highest EV-to-Revenue of Galapagos NV was 48.38. The lowest was -8.31. And the median was 12.23.

GLPG's EV-to-Revenue is ranked better than
96.32% of 1032 companies
in the Biotechnology industry
Industry Median: 7.64 vs GLPG: -7.98

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

As of today (2024-04-24), Galapagos NV's stock price is $28.77. Galapagos NV's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 was $3.82. Therefore, Galapagos NV's PS Ratio for today is 7.53.


Galapagos NV EV-to-Revenue Historical Data

The historical data trend for Galapagos NV's EV-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Galapagos NV EV-to-Revenue Chart

Galapagos NV Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EV-to-Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only 7.55 0.28 -6.19 -5.60 -5.16

Galapagos NV Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
EV-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -5.60 -5.80 -4.72 -5.91 -5.16

Competitive Comparison of Galapagos NV's EV-to-Revenue

For the Biotechnology subindustry, Galapagos NV's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Galapagos NV's EV-to-Revenue Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Galapagos NV's EV-to-Revenue distribution charts can be found below:

* The bar in red indicates where Galapagos NV's EV-to-Revenue falls into.



Galapagos NV EV-to-Revenue Calculation

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

Galapagos NV's EV-to-Revenue for today is calculated as:

EV-to-Revenue=Enterprise Value (Today)/Revenue (TTM)
=-2038.527/254.015
=-8.03

Galapagos NV's current Enterprise Value is $-2,038.5 Mil.
Galapagos NV's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $254.0 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Galapagos NV  (NAS:GLPG) EV-to-Revenue Explanation

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

Galapagos NV's PS Ratiofor today is calculated as:

PS Ratio=Share Price (Today)/Revenue per Share (TTM)
=28.77/3.82
=7.53

Galapagos NV's share price for today is $28.77.
Galapagos NV's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $3.82.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Galapagos NV EV-to-Revenue Related Terms

Thank you for viewing the detailed overview of Galapagos NV's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Galapagos NV (Galapagos NV) Business Description

Address
Generaal De Wittelaan L11 A3, Mechelen, BEL, 2800
Galapagos NV is a clinical-stage biotechnology company, involved in the discovery and development of small-molecule medicines. The company's product candidate portfolio includes Filgotinib, a JAK1 inhibitor to treat rheumatoid arthritis, Crohn's disease, and ulcerative colitis; novel therapies in cystic fibrosis (a chronic disease that affects the lungs and digestive system); GLPG1690, a selective autotaxin inhibitor with potential application in idiopathic pulmonary disease; GLPG1972 to treat osteoarthritis; and MOR106 to treat atopic dermatitis.